CUTIA-B (02487) and Hangzhou Guansu entered into a supplementary agreement regarding the cooperation rights and revenue sharing arrangements for CU-20401 in regions outside Asia.

CUTIA-B (02487) announced that, in relation to the cooperation agreement entered into between the Company and Hangzhou Guansu Biotechnology Co., Ltd. (Hangzhou Guansu) on August 28, 2020 regarding CU-20401 (recombinant mutant collagenase), and the announcement regarding the completion of the Phase II clinical trial of CU-20401 in China. Pursuant to the original agreement, Hangzhou Guansu exclusively transferred to the Company all intellectual property rights and development results relating to CU-20401 in the Asian region, and the Company also reached a joint cooperation with Hangzhou Guansu on clinical development in the Asian region. The Board is pleased to announce that the Company has entered into a supplementary agreement with Hangzhou Guansu to adjust the cooperation rights and revenue sharing arrangements for CU-20401 in regions outside Asia (the "Extraterritorial Regions"). Pursuant to the supplementary agreement, the Company and Hangzhou Guansu agreed to expand the geographical scope under the original agreement from the Asian region to the Extraterritorial Regions. Both the Company and Hangzhou Guansu have the right to seek third-party partners in the Extraterritorial Regions to carry out out-licensing/sublicensing cooperation. The Company and Hangzhou Guansu also agreed to further strengthen the shared cooperation terms, including clinical, registration, and research and development, in order to accelerate the development, registration, and commercialization of CU-20401 in the Extraterritorial Regions.